Orasis Pharmaceuticals Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Angelini Licenses Cureverse’s Nov

PureTech Health plc, after the multibillion-dollar success of its last neuropsychiatry venture Karuna Therapeutics Inc., launched Seaport Therapeutics in April with $100m in series A funding and on 21

LENZ Therapeutics has picked out the eye drop LNZ100 as its lead candidate for presbyopia and is confident it has a large potential commercial market, with new Phase III data showing rapid improvemen

AbbVie Inc. will have direct competition for its presbyopia product Vuity, since privately held Orasis Pharmaceuticals Ltd. got US Food and Drug Administration approval for the same indication on 1